

Konstantinos Pateras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5270229/publications.pdf>

Version: 2024-02-01

22
papers

342
citations

933447

10
h-index

839539

18
g-index

27
all docs

27
docs citations

27
times ranked

559
citing authors

#	ARTICLE	IF	CITATIONS
1	Normal ranges of left atrial volumes and ejection fraction by 3D echocardiography in adults: a systematic review and meta-analysis. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 1329-1340.	1.5	6
2	tPriors : a tool for prior elicitation and obtaining posterior distributions of true disease prevalence. <i>BMC Medical Research Methodology</i> , 2022, 22, 91.	3.1	1
3	Hierarchical true prevalence, risk factors and clinical symptoms of tuberculosis among suspects in Bangladesh. <i>PLoS ONE</i> , 2022, 17, e0262978.	2.5	1
4	A Bayesian meta-analysis on early tobacco exposure and vascular health: From childhood to early adulthood. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1315-1322.	1.8	5
5	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1067-1076.	2.6	40
6	Prior distributions for variance parameters in a sparse-event meta-analysis of a few small trials. <i>Pharmaceutical Statistics</i> , 2021, 20, 39-54.	1.3	8
7	Deriving cut-off values for continuous predictors of severe outcomes in COVID-19 through meta-analysis of individual studies: A comment on the article by Hariyanto et al.. <i>American Journal of Emergency Medicine</i> , 2021, 50, 799.	1.6	1
8	Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis. <i>European Journal of Internal Medicine</i> , 2021, 85, 130-132.	2.2	7
9	Combined assessment of early and late-phase outcomes in orphan drug development. <i>Statistics in Medicine</i> , 2021, 40, 2957-2974.	1.6	2
10	Wenckebach cycle length: A novel predictor for AV block in AVNRT patients treated with ablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1497-1503.	1.2	4
11	Atrial High-Rate Episode Duration Thresholds and Thromboembolic Risk: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e022487.	3.7	17
12	The epidemic volatility index, a novel early warning tool for identifying new waves in an epidemic. <i>Scientific Reports</i> , 2021, 11, 23775.	3.3	10
13	The Complex Relationship Between Serum Uric Acid, Endothelial Function and Small Vessel Remodeling in Humans. <i>Journal of Clinical Medicine</i> , 2020, 9, 2027.	2.4	12
14	Antithrombotic treatment in patients with stroke and supracardiac atherosclerosis. <i>Neurology</i> , 2020, 95, e499-e507.	1.1	7
15	Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2587-2598.	4.4	63
16	Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale. <i>Stroke</i> , 2019, 50, 3135-3140.	2.0	16
17	Participants' outcomes gone missing within a network of interventions: Bayesian modeling strategies. <i>Statistics in Medicine</i> , 2019, 38, 3861-3879.	1.6	7
18	Association between fat mass through adolescence and arterial stiffness: a population-based study from The Avon Longitudinal Study of Parents and Children. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 474-481.	5.6	45

#	ARTICLE	IF	CITATIONS
19	Interval estimation of the overall treatment effect in a meta-analysis of a few small studies with zero events. Contemporary Clinical Trials Communications, 2018, 9, 98-107.	1.1	16
20	Data-generating models of dichotomous outcomes: Heterogeneity in simulation studies for a random-effects meta-analysis. Statistics in Medicine, 2018, 37, 1115-1124.	1.6	32
21	Applicability and added value of novel methods to improve drug development in rare diseases. Orphanet Journal of Rare Diseases, 2018, 13, 200.	2.7	12
22	Amyloid- β (1-40) and Mortality in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Annals of Internal Medicine, 2018, 168, 855.	3.9	29